Please enable JavaScript to continue using this application.

Compare $GRAL vs $RYTM | Chartloom

Compare

$GRAL vs $RYTM

Grail Inc · Rhythm Pharmaceuticals Inc

GRAL

Grail Inc

RYTM

Rhythm Pharmaceuticals Inc

Compare $GRAL vs $RYTM

Comparing Grail Inc and Rhythm Pharmaceuticals Inc

GRALGrail Inc

RYTMRhythm Pharmaceuticals Inc

GRALGrail Inc

Market cap

$6.03B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

29.71x

Rev growth (TTM)

23.1%

YTD performance

58.2%

52W performance

123.8%

FCF yield

-4.9%

RYTMRhythm Pharmaceuticals Inc

Market cap

$6.22B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

15.08x

Rev growth (TTM)

53.5%

YTD performance

-13.6%

52W performance

-9.4%

FCF yield

-1.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GRAL

RYTM

Detailed metrics comparison

GRAL

Grail Inc

RYTM

Rhythm Pharmaceuticals Inc

Market Cap

GRAL$6.03B

RYTM$6.22B

Enterprise Value

GRAL$5.98B

RYTM$6.26B

Price

GRAL$140.58

RYTM$90.78

P/E Ratio

GRALN/A

RYTMN/A

P/S Ratio

GRAL36.51x

RYTM25.93x

EV/Sales

GRAL36.17x

RYTM26.10x

EV/EBITDA

GRAL0.00x

RYTM0.00x

P/B Ratio

GRAL2.52x

RYTM29.41x

P/FCF Ratio

GRALN/A

RYTMN/A

EV/FCF

GRAL-20.19x

RYTM-58.90x

PEG Ratio

GRALN/A

RYTMN/A

Forward P/E (NTM)

GRALN/A

RYTMN/A

Forward P/S (NTM)

GRAL29.71x

RYTM15.08x

Revenue (TTM)

GRAL$165M

RYTM$240M

Revenue Growth (YoY)

GRAL23.1%

RYTM53.5%

Forward Rev Growth

GRAL25.3%

RYTM77.4%

Gross Margin (TTM)

GRAL49.7%

RYTM70.9%

Operating Margin (TTM)

GRAL0.0%

RYTM0.0%

EBITDA Margin (TTM)

GRAL-229.0%

RYTM-83.2%

Net Margin (TTM)

GRAL-236.9%

RYTM-87.6%

FCF Margin (TTM)

GRAL-179.2%

RYTM-44.3%

Net Income (TTM)

GRAL$-392M

RYTM$-210M

FCF (TTM)

GRAL$-296M

RYTM$-106M

EPS (TTM)

GRAL-$9.08

RYTM-$3.06

ROE (TTM)

GRAL-1588.0%

RYTM-8048.0%

ROA (TTM)

GRAL-1402.0%

RYTM-4400.0%

ROIC (TTM)

GRAL-1588.0%

RYTM-5656.0%

Cash

GRAL$56M

RYTM$66M

Debt

GRAL$0

RYTM$106M

Net Cash/Debt

GRAL$56M

RYTM$-40M

Current Ratio (TTM)

GRAL10.95x

RYTM3.45x

Quick Ratio (TTM)

GRAL10.55x

RYTM3.00x

Debt/Equity (TTM)

GRAL0.00x

RYTM0.49x

Debt/Assets (TTM)

GRAL0.0%

RYTM0.0%

Interest Coverage (TTM)

GRALN/A

RYTMN/A

Net Debt/EBITDA (TTM)

GRAL0.00x

RYTM0.00x

Beta

GRAL2.04

RYTM2.13

52W Performance

GRAL123.8%

RYTM-9.4%

YTD Performance

GRAL58.2%

RYTM-13.6%

% from 52W High

GRAL-15.6%

RYTM-25.7%

% from 52W Low

GRAL238.7%

RYTM21.9%

Asset Turnover (TTM)

GRAL0.06x

RYTM0.51x

FCF Yield (TTM)

GRAL-4.9%

RYTM-1.7%

Earnings Yield (TTM)

GRAL-6.5%

RYTM-3.4%

Dividend Yield (TTM)

GRALN/A

RYTMN/A

Rule of 40

GRAL-156.1

RYTM9.2

EV/GP/RG

GRAL2.75

RYTM0.49

Ticker research

View GRAL research View RYTM research

Metric	GRAL Grail Inc	RYTM Rhythm Pharmaceuticals Inc
Market & Valuation
Market Cap	$6.03B	$6.22B
Enterprise Value	$5.98B	$6.26B
Price	$140.58	$90.78
P/E Ratio	N/A	N/A
P/S Ratio	36.51x	25.93x
EV/Sales	36.17x	26.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.52x	29.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-20.19x	-58.90x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	29.71x	15.08x
Revenue & Growth
Revenue (TTM)	$165M	$240M
Revenue Growth (YoY)	23.1%	53.5%
Forward Rev Growth	25.3%	77.4%
Profitability
Gross Margin (TTM)	49.7%	70.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-229.0%	-83.2%
Net Margin (TTM)	-236.9%	-87.6%
FCF Margin (TTM)	-179.2%	-44.3%
Net Income (TTM)	$-392M	$-210M
FCF (TTM)	$-296M	$-106M
EPS (TTM)	-$9.08	-$3.06
ROE (TTM)	-1588.0%	-8048.0%
ROA (TTM)	-1402.0%	-4400.0%
ROIC (TTM)	-1588.0%	-5656.0%
Financial Health
Cash	$56M	$66M
Debt	$0	$106M
Net Cash/Debt	$56M	$-40M
Current Ratio (TTM)	10.95x	3.45x
Quick Ratio (TTM)	10.55x	3.00x
Debt/Equity (TTM)	0.00x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.04	2.13
52W Performance	123.8%	-9.4%
YTD Performance	58.2%	-13.6%
% from 52W High	-15.6%	-25.7%
% from 52W Low	238.7%	21.9%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.51x
FCF Yield (TTM)	-4.9%	-1.7%
Earnings Yield (TTM)	-6.5%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-156.1	9.2
EV/GP/RG	2.75	0.49
Ticker research	View GRAL research	View RYTM research

Valuation

P/S Ratio

RYTM

25.93x

GRAL

36.51x

EV/FCF

RYTM

-58.90x

GRAL

-20.19x

Growth & revenue

Revenue Growth TTM

RYTM

53.5%

GRAL

23.1%

Forward Revenue Growth

RYTM

77.4%

GRAL

25.3%

Profitability & performance

Gross Margin

RYTM

70.9%

GRAL

49.7%

ROE

GRAL

-1588.0%

RYTM

-8048.0%

FCF Yield %

RYTM

-1.7%

GRAL

-4.9%

52-Week Performance

GRAL

123.8%

RYTM

-9.4%

Detailed metrics comparison

GRAL

Grail Inc

RYTM

Rhythm Pharmaceuticals Inc

Market Cap

GRAL$6.03B

RYTM$6.22B

Enterprise Value

GRAL$5.98B

RYTM$6.26B

Price

GRAL$140.58

RYTM$90.78

P/E Ratio

GRALN/A

RYTMN/A

P/S Ratio

GRAL36.51x

RYTM25.93x

EV/Sales

GRAL36.17x

RYTM26.10x

EV/EBITDA

GRAL0.00x

RYTM0.00x

P/B Ratio

GRAL2.52x

RYTM29.41x

P/FCF Ratio

GRALN/A

RYTMN/A

EV/FCF

GRAL-20.19x

RYTM-58.90x

PEG Ratio

GRALN/A

RYTMN/A

Forward P/E (NTM)

GRALN/A

RYTMN/A

Forward P/S (NTM)

GRAL29.71x

RYTM15.08x

Revenue (TTM)

GRAL$165M

RYTM$240M

Revenue Growth (YoY)

GRAL23.1%

RYTM53.5%

Forward Rev Growth

GRAL25.3%

RYTM77.4%

Gross Margin (TTM)

GRAL49.7%

RYTM70.9%

Operating Margin (TTM)

GRAL0.0%

RYTM0.0%

EBITDA Margin (TTM)

GRAL-229.0%

RYTM-83.2%

Net Margin (TTM)

GRAL-236.9%

RYTM-87.6%

FCF Margin (TTM)

GRAL-179.2%

RYTM-44.3%

Net Income (TTM)

GRAL$-392M

RYTM$-210M

FCF (TTM)

GRAL$-296M

RYTM$-106M

EPS (TTM)

GRAL-$9.08

RYTM-$3.06

ROE (TTM)

GRAL-1588.0%

RYTM-8048.0%

ROA (TTM)

GRAL-1402.0%

RYTM-4400.0%

ROIC (TTM)

GRAL-1588.0%

RYTM-5656.0%

Cash

GRAL$56M

RYTM$66M

Debt

GRAL$0

RYTM$106M

Net Cash/Debt

GRAL$56M

RYTM$-40M

Current Ratio (TTM)

GRAL10.95x

RYTM3.45x

Quick Ratio (TTM)

GRAL10.55x

RYTM3.00x

Debt/Equity (TTM)

GRAL0.00x

RYTM0.49x

Debt/Assets (TTM)

GRAL0.0%

RYTM0.0%

Interest Coverage (TTM)

GRALN/A

RYTMN/A

Net Debt/EBITDA (TTM)

GRAL0.00x

RYTM0.00x

Beta

GRAL2.04

RYTM2.13

52W Performance

GRAL123.8%

RYTM-9.4%

YTD Performance

GRAL58.2%

RYTM-13.6%

% from 52W High

GRAL-15.6%

RYTM-25.7%

% from 52W Low

GRAL238.7%

RYTM21.9%

Asset Turnover (TTM)

GRAL0.06x

RYTM0.51x

FCF Yield (TTM)

GRAL-4.9%

RYTM-1.7%

Earnings Yield (TTM)

GRAL-6.5%

RYTM-3.4%

Dividend Yield (TTM)

GRALN/A

RYTMN/A

Rule of 40

GRAL-156.1

RYTM9.2

EV/GP/RG

GRAL2.75

RYTM0.49

Ticker research

View GRAL research View RYTM research

Metric	GRAL Grail Inc	RYTM Rhythm Pharmaceuticals Inc
Market & Valuation
Market Cap	$6.03B	$6.22B
Enterprise Value	$5.98B	$6.26B
Price	$140.58	$90.78
P/E Ratio	N/A	N/A
P/S Ratio	36.51x	25.93x
EV/Sales	36.17x	26.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.52x	29.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-20.19x	-58.90x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	29.71x	15.08x
Revenue & Growth
Revenue (TTM)	$165M	$240M
Revenue Growth (YoY)	23.1%	53.5%
Forward Rev Growth	25.3%	77.4%
Profitability
Gross Margin (TTM)	49.7%	70.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-229.0%	-83.2%
Net Margin (TTM)	-236.9%	-87.6%
FCF Margin (TTM)	-179.2%	-44.3%
Net Income (TTM)	$-392M	$-210M
FCF (TTM)	$-296M	$-106M
EPS (TTM)	-$9.08	-$3.06
ROE (TTM)	-1588.0%	-8048.0%
ROA (TTM)	-1402.0%	-4400.0%
ROIC (TTM)	-1588.0%	-5656.0%
Financial Health
Cash	$56M	$66M
Debt	$0	$106M
Net Cash/Debt	$56M	$-40M
Current Ratio (TTM)	10.95x	3.45x
Quick Ratio (TTM)	10.55x	3.00x
Debt/Equity (TTM)	0.00x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.04	2.13
52W Performance	123.8%	-9.4%
YTD Performance	58.2%	-13.6%
% from 52W High	-15.6%	-25.7%
% from 52W Low	238.7%	21.9%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.51x
FCF Yield (TTM)	-4.9%	-1.7%
Earnings Yield (TTM)	-6.5%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-156.1	9.2
EV/GP/RG	2.75	0.49
Ticker research	View GRAL research	View RYTM research